Creyon and Cajal Enter Partnership to Develop ASOs for Neurodegenerative Diseases

Rare Daily Staff

Creyon Bio and Cajal Neuroscience have entered a partnership to develop novel antisense oligonucleotide medicines for neurodegenerative diseases.

Under the collaboration, Cajal is responsible for nominating targets and mechanisms of action based on therapeutic insights from its discovery platform that combines genetics with human multi-omics, longitudinal clinical data, and high-throughput biology. Creyon is responsible for engineering therapeutic candidates leveraging its platform technology to create oligonucleotide-based medicines with optimal pharmacological properties that are designed to minimize side effects.

Cajal will complete validation and IND-enabling studies of the lead therapeutic candidates.

The two companies have initiated and successfully advanced multiple programs, including one program nearing IND-enabling studies.

“We are well positioned to accelerate the development of much needed therapies for patients with common neurodegenerative disorders by combining Cajal’s target identification capabilities with our platform designed to engineer safe, effective, and ultimately best-in-class compounds,” said Chris Hart, co-founder and CEO of Creyon Bio. “This synergy between innovative target discovery capabilities and expert engineering of oligonucleotide-based medicines illustrates the strategic value of collaboration to advance new treatments for a myriad of diseases where there is high unmet need.”

Photo: Chris Hart, co-founder and CEO of Creyon Bio